IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 77.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 195,842 shares of the company’s stock after selling 655,708 shares during the period. Price T Rowe Associates Inc. MD owned about 0.24% of IDEXX Laboratories worth $63,806,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. FMR LLC lifted its stake in IDEXX Laboratories by 82.5% during the second quarter. FMR LLC now owns 2,067,814 shares of the company’s stock worth $725,243,000 after purchasing an additional 934,829 shares during the last quarter. BlackRock Inc. lifted its position in shares of IDEXX Laboratories by 4.2% during the 3rd quarter. BlackRock Inc. now owns 8,792,300 shares of the company’s stock worth $2,864,533,000 after buying an additional 358,427 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of IDEXX Laboratories by 743.0% in the 2nd quarter. Renaissance Technologies LLC now owns 217,504 shares of the company’s stock valued at $76,285,000 after buying an additional 191,704 shares in the last quarter. Brown Advisory Inc. grew its position in shares of IDEXX Laboratories by 16.4% in the 3rd quarter. Brown Advisory Inc. now owns 1,212,028 shares of the company’s stock valued at $394,880,000 after buying an additional 170,834 shares during the last quarter. Finally, Echo Street Capital Management LLC raised its stake in IDEXX Laboratories by 65.7% during the 3rd quarter. Echo Street Capital Management LLC now owns 421,416 shares of the company’s stock worth $137,297,000 after acquiring an additional 167,164 shares in the last quarter. 87.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Kathy V. Turner sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 14th. The stock was sold at an average price of $504.59, for a total value of $1,009,180.00. Following the sale, the senior vice president now owns 7,380 shares in the company, valued at approximately $3,723,874.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other IDEXX Laboratories news, SVP Kathy V. Turner sold 2,000 shares of the business’s stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of $504.59, for a total transaction of $1,009,180.00. Following the sale, the senior vice president now directly owns 7,380 shares in the company, valued at $3,723,874.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Kathy V. Turner sold 1,000 shares of the company’s stock in a transaction on Thursday, February 9th. The shares were sold at an average price of $505.04, for a total value of $505,040.00. Following the completion of the sale, the senior vice president now directly owns 6,941 shares in the company, valued at approximately $3,505,482.64. The disclosure for this sale can be found here. Insiders own 2.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IDXX. Barclays raised their price objective on IDEXX Laboratories from $582.00 to $590.00 and gave the stock an “overweight” rating in a report on Wednesday, February 8th. Morgan Stanley cut their price target on IDEXX Laboratories from $573.00 to $543.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 15th. JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $525.00 to $550.00 and gave the company an “overweight” rating in a report on Tuesday, February 7th. Atlantic Securities lifted their target price on shares of IDEXX Laboratories from $470.00 to $600.00 and gave the company an “overweight” rating in a report on Tuesday, February 7th. Finally, TheStreet upgraded shares of IDEXX Laboratories from a “c+” rating to a “b-” rating in a research note on Friday, November 25th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $514.75.

IDEXX Laboratories Trading Up 1.3 %

NASDAQ:IDXX opened at $460.92 on Tuesday. IDEXX Laboratories, Inc. has a 1 year low of $317.06 and a 1 year high of $560.92. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.59 and a current ratio of 0.89. The stock has a fifty day moving average price of $477.75 and a two-hundred day moving average price of $412.25. The stock has a market capitalization of $38.21 billion, a price-to-earnings ratio of 57.40, a PEG ratio of 2.64 and a beta of 1.18.

IDEXX Laboratories (NASDAQ:IDXX – Get Rating) last announced its quarterly earnings results on Monday, February 6th. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.92 by $0.13. IDEXX Laboratories had a net margin of 20.17% and a return on equity of 124.51%. The business had revenue of $828.60 million during the quarter, compared to the consensus estimate of $820.91 million. During the same quarter last year, the firm posted $1.89 EPS. The business’s revenue was up 3.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 9.58 earnings per share for the current fiscal year.

About IDEXX Laboratories

(Get Rating)

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other.